Evergraf 0.25mg tablet - Everolimus | Myapplepharma
DESCRIPTION
Evergraf 0.25mg belongs to the class of anti-cancer drugsEvergraf 0.25mg contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down.
Evergraf 0.25mg tablets is not a curable medication, which helps to slow their spreading into the body.
PRESCRIBED FOR
The drug Evergraf 0.25mg is mainly used for the treatment of the following disease• kidney carcinoma
• Breast carcinoma
• Brain carcinoma
Evergraf 0.25mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas.
CLINICAL PHARMACOLOGY OF EVERGRAF
Everolimus is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis. Evergraf also prohibits the expression of hypoxia-inducible factor, causing to a reduces in the expression of vascular endothelial growth factor. The result of everolimus prevention of mTOR is a reduction in cell multiplication, angiogenesis, and glucose uptake.DOSAGE
Evergraf tablets should be given with or without foodIn breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in brain or intracranial tumor is 4.5mg/m2 should be given orally.
Drug-Drug interaction
Interaction of Evergraf 0.25mg with a strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.Concomitant use of Evergraf 0.25mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Interaction of Evergraf 0.25mg with cyclosporine will increase the AUC level of Everolimus frequently.
Interaction of ketoconazole with Evergraf 0.25mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.
LACTATION
Breastfeeding should not be suggestedSTORAGE
Evergraf 0.25mg tablet store at 25°. Protect the medicine away from moisture, heat, and light.OVERDOSAGE
The over dosage of Everolimus is limited If overdosage occurs patient must be provided with supportive measures. And monitor evidence of toxicity in Everolimus overdosageMISSED DOSE
If the patients missed the dose, patients must consult with the medical practitioner and follow the instructions given by them.Or missed dose should be avoided and follow the regular dosing schedule.
Comments
Post a Comment